Skip to main content

Table 2 Susceptibilities

From: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Antimicrobial Number susceptible (n = 108)
New agents  
Cefiderocol 108 (100%)
Ceftazidime-avibactam 108 (100%)
Ceftolozane-tazobactam 105 (97%)
Fosfomycin 104 (96%)
Plazomicin 108 (100%)
Standard agents  
Amikacin 108 (100%)
Gentamicin 72 (67%)
Tobramycin 61 (56%)
Piperacillin-tazobactam 99 (92%)
Ceftazidime 46 (43%)
Ceftriaxone 0 (0%)
Ertapenem 103 (95%)
Meropenem 108 (100%)
Ciprofloxacin 43 (40%)
Trimethoprim-sulfamethoxazole 44 (41%)